FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 | |
|-------------|------|-------|--|

| STATEMENT | OF (| CHANGES | IN BENEFICIAL | OWNERSHIP |
|-----------|------|---------|---------------|------------------|

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0 | | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* O'Mahony John Mark | | | | | 2. Issuer Name and Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [LPTX] | | | | | (Che | ck all application | • | | wner | | |
|---|--------|---------------|------------------------|-------------|--|---------|---|--|---|--|--|---|------------------------|---|---|--|
| (Last) (First) (Middle) C/O LEAP THERAPEUTICS, INC. 47 THORNDIKE STREET SUITE B1-1 | | | | 0 | 3. Date of Earliest Transaction (Month/Day/Year) 03/31/2023 | | | | | | | below) Chie | f Manufac | er | | |
| (Street) CAMBRIDGE MA 02141 (City) (State) (Zip) | | | | 4 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | 6. In Line |) Form fil Form fil | ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date | | | Transacti ite | | | | 3. Transacti Code (Ins | ansaction ode (Instr. Disposed Of (D) (Instr. 3, 2 | | | ed (A) or tr. 3, 4 and 5 | 5. Amoun | s Ily ollowing (| 5. Ownership Form: Direct D) or Indirect I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | |
| | | Trans Code | ansaction Derivative E | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownersh Form: Direct (D) or Indirect (I) (Instr. | Beneficial Ownership t (Instr. 4) | | | | |
| | | | | Code | v | (A) | (D) | Date Exercisable | | iration | Title | Amount or Number of Shares | | (Instr. 4) | 11(5) | |
| Employee Stock Option (Right to Buy) | \$0.34 | 03/31/2023 | | A | | 500,000 | | (1) | 03/3 | 1/2033 | Common Stock | 500,000 | \$0 | 500,000 | D | |

Explanation of Responses:

1. The Option was granted pursuant to Leap's 2016 Equity Incentive Plan. By its terms, the Option shall vest and become exercisable for the shares underlying the Option in a series of 36 equal monthly installments for so long as the reporting person continues to be employed by or provides service to the Company, with the first of such monthly installments vesting on the one month anniversary of March 31, 2023, the Vesting Start Date.

> /s/ Douglas E. Onsi, as attorney-04/04/2023 in-fact for John Mark O'Mahony

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.